Benzaquen, M.; Munshi, M.; Bossart, S.; Feldmeyer, L.; Emelianov, V.; Yawalkar, N.; Cazzaniga, S.; Heidemeyer, K.
Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis. Bioengineering 2022, 9, 387.
https://doi.org/10.3390/bioengineering9080387
AMA Style
Benzaquen M, Munshi M, Bossart S, Feldmeyer L, Emelianov V, Yawalkar N, Cazzaniga S, Heidemeyer K.
Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis. Bioengineering. 2022; 9(8):387.
https://doi.org/10.3390/bioengineering9080387
Chicago/Turabian Style
Benzaquen, Michael, Mohammad Munshi, Simon Bossart, Laurence Feldmeyer, Vladimir Emelianov, Nikhil Yawalkar, Simone Cazzaniga, and Kristine Heidemeyer.
2022. "Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis" Bioengineering 9, no. 8: 387.
https://doi.org/10.3390/bioengineering9080387
APA Style
Benzaquen, M., Munshi, M., Bossart, S., Feldmeyer, L., Emelianov, V., Yawalkar, N., Cazzaniga, S., & Heidemeyer, K.
(2022). Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis. Bioengineering, 9(8), 387.
https://doi.org/10.3390/bioengineering9080387